BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28007907)

  • 1. H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.
    Hasumi H; Hasumi Y; Baba M; Nishi H; Furuya M; Vocke CD; Lang M; Irie N; Esumi C; Merino MJ; Kawahara T; Isono Y; Makiyama K; Warner AC; Haines DC; Wei MH; Zbar B; Hagenau H; Feigenbaum L; Kondo K; Nakaigawa N; Yao M; Metwalli AR; Marston Linehan W; Schmidt LS
    Hum Mol Genet; 2017 Jan; 26(2):354-366. PubMed ID: 28007907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn.
    Hasumi H; Baba M; Hasumi Y; Lang M; Huang Y; Oh HF; Matsuo M; Merino MJ; Yao M; Ito Y; Furuya M; Iribe Y; Kodama T; Southon E; Tessarollo L; Nagashima K; Haines DC; Linehan WM; Schmidt LS
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1624-31. PubMed ID: 25775561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
    Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
    J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterozygous germline FLCN mutation in Birt-Hogg-Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report.
    Li J; Liu F; Liu X; Hu Y; Liu Z; Shen Y; Wan J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2319-2325. PubMed ID: 36258004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of Birt-Hogg-Dubé syndrome implying reduced or no wild-type folliculin without mutated protein is pathogenic.
    Enomoto Y; Namba Y; Hoshika Y; Komemushi Y; Mitani K; Kume H; Kobayashi E; Miyama Y; Homma Y; Ushiku T; Seyama K
    Eur J Med Genet; 2020 Apr; 63(4):103820. PubMed ID: 31778855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
    Baba M; Furihata M; Hong SB; Tessarollo L; Haines DC; Southon E; Patel V; Igarashi P; Alvord WG; Leighty R; Yao M; Bernardo M; Ileva L; Choyke P; Warren MB; Zbar B; Linehan WM; Schmidt LS
    J Natl Cancer Inst; 2008 Jan; 100(2):140-54. PubMed ID: 18182616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Birt Hogg-Dubé syndrome-associated FLCN mutations disrupt protein stability.
    Nahorski MS; Reiman A; Lim DH; Nookala RK; Seabra L; Lu X; Fenton J; Boora U; Nordenskjöld M; Latif F; Hurst LD; Maher ER
    Hum Mutat; 2011 Aug; 32(8):921-9. PubMed ID: 21538689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.
    Schmidt LS
    Fam Cancer; 2013 Sep; 12(3):357-64. PubMed ID: 23108783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.
    Tee AR; Pause A
    Fam Cancer; 2013 Sep; 12(3):367-72. PubMed ID: 23096221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folliculin variants linked to Birt-Hogg-Dubé syndrome are targeted for proteasomal degradation.
    Clausen L; Stein A; Grønbæk-Thygesen M; Nygaard L; Søltoft CL; Nielsen SV; Lisby M; Ravid T; Lindorff-Larsen K; Hartmann-Petersen R
    PLoS Genet; 2020 Nov; 16(11):e1009187. PubMed ID: 33137092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
    Houweling AC; Gijezen LM; Jonker MA; van Doorn MB; Oldenburg RA; van Spaendonck-Zwarts KY; Leter EM; van Os TA; van Grieken NC; Jaspars EH; de Jong MM; Bongers EM; Johannesma PC; Postmus PE; van Moorselaar RJ; van Waesberghe JH; Starink TM; van Steensel MA; Gille JJ; Menko FH
    Br J Cancer; 2011 Dec; 105(12):1912-9. PubMed ID: 22146830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.
    Nagashima K; Fukushima H; Shimizu K; Yamada A; Hidaka M; Hasumi H; Ikebe T; Fukumoto S; Okabe K; Inuzuka H
    Oncotarget; 2017 Feb; 8(6):9947-9960. PubMed ID: 28039480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome.
    Benhammou JN; Vocke CD; Santani A; Schmidt LS; Baba M; Seyama K; Wu X; Korolevich S; Nathanson KL; Stolle CA; Linehan WM
    Genes Chromosomes Cancer; 2011 Jun; 50(6):466-77. PubMed ID: 21412933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.
    Schneider M; Dinkelborg K; Xiao X; Chan-Smutko G; Hruska K; Huang D; Sagar P; Harisinghani M; Iliopoulos O
    Fam Cancer; 2018 Jan; 17(1):135-139. PubMed ID: 28623476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein.
    Laviolette LA; Mermoud J; Calvo IA; Olson N; Boukhali M; Steinlein OK; Roider E; Sattler EC; Huang D; Teh BT; Motamedi M; Haas W; Iliopoulos O
    Nat Commun; 2017 Jun; 8():15866. PubMed ID: 28656962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.
    Dong L; Gao M; Hao WJ; Zheng XQ; Li YG; Li XL; Yu Y
    Medicine (Baltimore); 2016 May; 95(22):e3695. PubMed ID: 27258496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.